Did Pacira BioSciences beat or miss consensus estimates last quarter?

What does Pacira BioSciences do and what are its main business segments?

What is Pacira BioSciences's gross profit margin?

What is the revenue and EPS growth rate for Pacira BioSciences year over year?

What is the market's earnings forecast for Pacira BioSciences next quarter?

What guidance did Pacira BioSciences's management provide for the next earnings period?

What factors drove the changes in Pacira BioSciences's revenue and profit?

What were the key takeaways from Pacira BioSciences's earnings call?

- **Revenue Growth**: 6% YoY driven by 9% EXPAREL volume (highest in 3 years) and 82% gross margin
- **Strategic Investments**: $50M share buyback, AMT-143 licensing for 14-day analgesia, and Phase II PCRX-201 gene therapy
- **Pipeline Momentum**: 100M+ covered lives for EXPAREL, 3-year OA registry data showing opioid reduction, and J&J partnership accelerating Zilretta adoption
- **Risk Mitigation**: 21st EXPAREL patent and disciplined IP defense against generics

**【Management Opening Remarks】**
- CEO Frank Lee highlighted 6% year-over-year revenue growth, driven by 9% volume growth in EXPAREL and 82% non-GAAP gross margin. The company emphasized its 5x30 strategy for 5-year, 30% CAGR growth through commercial expansion and pipeline innovation.

**【CEO Commentary】**
- Reported strong execution across commercial and clinical initiatives, including EXPAREL volume growth of 9% (highest in 3 years) and 100 million+ covered lives via separate reimbursement policies. Discussed strategic investments in AMT-143 (long-acting bupivacaine) and Phase II PCRX-201 gene therapy for OA pain. Highlighted 21st EXPAREL patent listing and disciplined IP protection against generics.

**【CFO Financial Commentary】**
- GAAP net income: $420M; Non-GAAP EPS: $1.08 (vs. $0.95 prior). Gross margin improved to 82% (vs. 78% prior) due to manufacturing scale. R&D/Sales & Marketing expenses: $22.5M/$81.7M, up 30% YoY. Completed $50M share buyback, with $200M remaining under 2026 authorization. Raised 2025 guidance: Revenue $725M-$735M, EBITDA $49.4M.

**【Q&A Highlights】**
- **GPO Impact**: 9% EXPAREL volume growth offset by 3% ASP decline; expect convergence of volume/revenue growth in 2026. 
- **AMT-143 Licensing**: 14-day analgesia via hydrogel depot; Phase II planned for 2026. 
- **Zilretta Momentum**: J&J partnership driving access; 2026 Phase II for shoulder OA. 
- **Gene Therapy Perception**: PCRX-201 safety data (no neutralizing antibodies) and 3-year durability reduce skepticism.

Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript

- **Revenue Growth Acceleration**: Q2 EXPAREL volume up 6% YoY, narrowing full-year guidance to $730-750 million.
- **Gross Margin Expansion**: Q2 non-GAAP gross margin improved to 82%, with 2025 guidance raised to 78-80%.
- **Strategic Partnership Impact**: J&J MedTech collaboration doubles ZILRETTA reach, targeting 2026 growth in sports medicine and rheumatology.
- **Pipeline Momentum**: PCRX-201 Phase II study on track, with 3-year data showing sustained efficacy and safety.
- **Financial Strength**: $54.3 million adjusted EBITDA, $250 million remaining under share buyback program.

**【CEO Summary Section】**
- **Revenue Growth and Strategy**: Q2 2025 revenue growth driven by 6% year-over-year volume increase for EXPAREL, narrowing full-year guidance to $730-750 million. Emphasis on 5x30 strategy (5 partnerships by 2030) and pipeline innovation, including PCRX-201 with 3-year data showing sustained efficacy.
- **Market Access and IP**: CMS policy changes enabling outpatient EXPAREL use, with 40 million commercial lives covered (targeting 60 million by year-end). IP portfolio strengthened with reissued 495 patent and new erucic acid patents.
- **Partnerships**: J&J MedTech collaboration for ZILRETTA doubles sales reach, targeting sports medicine, pain management, and rheumatology markets.

**【CFO Financial Commentary】**
- **Financial Highlights**: Q2 non-GAAP gross margin improved to 82% (vs. 76% in 2024), driven by manufacturing efficiencies. Adjusted EBITDA of $54.3 million. Share buybacks of $50 million executed, with $250 million remaining under 2026 authorization.
- **Expense Management**: R&D up 34% to $24.7 million (due to PCRX-201 Phase II study), SG&A up 31% to $77.2 million (commercial investments). New $300 million credit facility reduces interest costs by 60 basis points annually.
- **Guidance Update**: Full-year non-GAAP gross margin raised to 78-80% (from 76-78%), reflecting royalty elimination and cost savings.

**【Q&A Key Highlights】**
- **J&J Partnership Economics**: Doubling ZILRETTA sales calls, with benefits expected in 2026. J&J's broader customer base expands access to sports medicine and rheumatology segments.
- **Gross to Net Impact**: Low single-digit (1%) impact on margins, manageable within guidance.
- **Pipeline Progress**: PCRX-201 Phase II ASCEND study on track for Part A completion by year-end, with 3-year data showing sustained efficacy and safety.
- **Surgery Volumes**: Outpatient case volumes slightly down Q2 vs. 2024, but EXPAREL growth outpacing market in community hospitals and ASCs.
- **International Expansion**: Actively pursuing partnerships for EXPAREL, ZILRETTA, and iovera°, targeting leaders in musculoskeletal pain markets.

Pacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call Transcript

- **EXPAREL Exclusivity Extended to 2039**: Settlement with Fresenius eliminates RDF royalties, improving gross margin by low single digits.
- **Gene Therapy Breakthrough**: PCRX-201 Phase 1 data shows 2-year pain reduction in knee OA, with 3-year follow-up data coming in 2025.
- **Robust Cash Flow**: $494M cash balance and $300M buyback program reflect confidence in 5x30 growth strategy.
- **Pipeline Investment**: 50%+ R&D spend on PCRX-201, with HCAd platform enabling novel local delivery for chronic pain.

**【CEO Opening Remarks】**
- **5x30 Strategy Progress**: Settled EXPAREL patent litigation with Fresenius, extending exclusivity to 2039. 18th patent listed in FDA Orange Book, eliminating RDF royalties (low single-digit margin improvement). Phase 2 PCRX-201 trial for knee OA dosing underway. GQ Bio acquisition adds gene therapy platform with 30,000bp DNA capacity.
- **EXPAREL Growth**: Q1 sales $136.5M (+3.1% YoY), daily volume +7% (adjusted for 2 fewer days). New J-code adoption driving 30%+ account expansion in ASCs and community hospitals. Gross margin benefit from RDF royalty elimination (~low single-digit %).
- **Pipeline Momentum**: PCRX-201 Phase 1 data shows 2-year pain reduction in knee OA (KL grade 4). HCAd platform enables local delivery with 10x lower dose than AAV vectors. ASCEND trial enrollment on track for 2026 readout.

**【CFO Financial Highlights】**
- **Revenue**: Q1 total revenue $164.9M (+3.1% YoY). EXPAREL +3.1%, ZILRETTA -9%, iovera +2%. Q1 2025 guidance reaffirmed ($725-765M).
- **Margins**: Non-GAAP gross margin 81% (vs. 72% 2024), driven by San Diego manufacturing scale. R&D expense $23.1M (+41% YoY) for PCRX-201 and ZILRETTA shoulder trial. SG&A $76.2M (+20% YoY) for commercial expansion.
- **Cash Flow**: $494M cash balance. $300M share buyback authorized (2025-2026). 2025 capex ~$20M for manufacturing capacity.

**【Q&A Key Takeaways】**
- **EXPAREL Penetration**: ~9% of 18M no pain-eligible procedures. Medicare accounts ~50% in hospitals, 75% in ASCs. 2025 growth driven by ASC adoption and IDN formulary wins.
- **Pipeline Capital Allocation**: 50%+ R&D spend on PCRX-201. HCAd platform could enable partnerships for non-core indications (e.g., spasticity, diabetic neuropathy).
- **Tariff Risk**: <10% of manufacturing in China, no material impact expected.
- **GPO Impact**: 2025 GPO contracts may reduce EXPAREL pricing by mid-single digits, offset by volume growth.
- **201 Clinical Feedback**: Docs seek 12+ months efficacy vs. current 3-6 months. PCRX-201 3-year data to be presented in 2025.


Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript

- **Record 2024 Growth**: $701M revenue, 5/30 strategy launched with 3+ million patient target by 2030.
- **EXPAREL Momentum**: J-code adoption, 40M+ commercial covered lives, 80% GPO coverage.
- **Pipeline Breakthroughs**: PCRX-201 Phase II study active, HCAd platform for gene therapy, 3-year data expected.
- **Financial Discipline**: 2025 guidance of $725M-$765M, 76%-78% gross margin, $125M buyback flexibility.
- **Innovation Focus**: $90M-$105M R&D investment for pipeline expansion, 5 partnerships sought.

**【CEO Summary Section】**
- Pacira achieved record 2024 revenue of $701 million, driven by EXPAREL, Zilretta, and iovera. Key milestones include CMS coverage for EXPAREL and iovera, RMAT designation for PCRX-201, and 72-patient Phase 1 data showing 2-year efficacy.
- 5/30 Strategy: Target 3+ million patients annually by 2030, double-digit CAGR, 5% gross margin expansion, 5 pipeline programs, and 5 partnerships.
- EXPAREL: J-code adoption early signs positive, 40M+ commercial covered lives, GPO contracts covering 80% of volume.
- Zilretta: Shoulder OA Phase III study enrolling, 4-month pain relief, 40% diabetic patient opportunity.
- iovera: C-98-09 code reimbursement, SmartTip launch for low back pain, spasticity study underway.
- GQ Bio acquisition: HCAd platform for gene therapy, PCRX-201 Phase II study active, 3-year follow-up data expected.

**【CFO Financial Commentary】**
- Q4 2024: EXPAREL ($147.7M), Zilretta ($33.1M), iovera ($6.5M). Non-GAAP gross margin 79%, R&D ($22.0M), SG&A ($78.6M), adjusted EBITDA ($62.5M).
- 2025 Guidance: Revenue $725M-$765M, gross margin 76%-78%, R&D $90M-$105M (11% YoY increase), SG&A $290M-$320M (8% YoY increase). Capital allocation focused on growth, pipeline, balance sheet, and $125M buyback.

**【Q&A Highlights】**
- **No Pain Uptake**: Early J-code adoption, 40M+ commercial covered lives, but full impact expected in H2 2025. IQVIA data lag 4 months.
- **Litigation & IP**: No generic launch expected, ongoing IP enforcement. New patents anticipated.
- **DTC Marketing**: Pilot programs launching H1 2025, ROI-driven investment to drive patient demand.
- **Pipeline Risk**: GQ Bio platform adds 5 preclinical programs, HCAd vector advantages (30kbp payload, lower dosing).

Pacira BioSciences (PCRX)-27 Feb 25-2024 Q4 Earnings call transcript

Pacira BioSciences (PCRX)-6 Nov 24-2024 Q3 Earnings call transcript

Pacira BioSciences (PCRX)-30 Jul 24-2024 Q2 Earnings call transcript

Pacira BioSciences (PCRX)-7 May 24-2024 Q1 Earnings call transcript

Pacira BioSciences (PCRX)-29 Feb 24-2023 Q4 Earnings call transcript

Pacira BioSciences (PCRX)-2 Aug 23-2023 Q2 Earnings call transcript

Pacira BioSciences (PCRX)-3 May 23-2023 Q1 Earnings call transcript

Pacira BioSciences (PCRX)-28 Feb 23-2022 Q4 Earnings call transcript

Pacira BioSciences (PCRX)-3 Nov 22-2022 Q3 Earnings call transcript

Pacira BioSciences (PCRX)-3 Aug 22-2022 Q2 Earnings call transcript

Pacira BioSciences (PCRX)-4 May 22-2022 Q1 Earnings call transcript

Pacira BioSciences (PCRX)-24 Feb 22-2021 Q4 Earnings call transcript

Pacira BioSciences (PCRX)-3 Nov 21-2021 Q3 Earnings call transcript

Pacira BioSciences (PCRX)-4 Aug 21-2021 Q2 Earnings call transcript

Pacira BioSciences (PCRX)-4 May 21-2021 Q1 Earnings call transcript

Pacira BioSciences (PCRX)-25 Feb 21-2020 Q4 Earnings call transcript

Pacira BioSciences (PCRX)-29 Oct 20-2020 Q3 Earnings call transcript

Pacira BioSciences (PCRX)-8 Aug 20-2020 Q2 Earnings call transcript

Pacira BioSciences (PCRX)-11 May 20-2020 Q1 Earnings call transcript

Pacira BioSciences (PCRX)-20 Feb 20-2019 Q4 Earnings call transcript

Pacira BioSciences (PCRX)-7 Nov 19-2019 Q3 Earnings call transcript

Pacira BioSciences (PCRX)-8 Aug 19-2019 Q2 Earnings call transcript

Pacira BioSciences (PCRX)-2 May 19-2019 Q1 Earnings call transcript

Pacira BioSciences (PCRX)-28 Feb 19-2018 Q4 Earnings call transcript

Pacira BioSciences (PCRX)-1 Nov 18-2018 Q3 Earnings call transcript

Pacira BioSciences (PCRX)-2 Aug 18-2018 Q2 Earnings call transcript

Pacira BioSciences (PCRX)-3 May 18-2018 Q1 Earnings call transcript

Pacira BioSciences (PCRX)-28 Feb 18-2017 Q4 Earnings call transcript

Pacira BioSciences (PCRX)-8 Nov 17-2017 Q3 Earnings call transcript

PCRX

PCRX fundamentals

Earnings Call

You can ask Aime